CollectionsMerck
IN THE NEWS

Merck

BUSINESS
July 18, 1997 | By Donna Shaw, INQUIRER STAFF WRITER
Shares of Merck & Co. Inc. rose more than 8 percent yesterday after the Whitehouse Station, N.J., pharmaceutical company announced better-than-expected profits for the second quarter. Investors also were encouraged that Merck's cholesterol-lowering drug Zocor was holding up against intense competition, although the rate by which it is growing is slowing. Even so, the number of patients taking the drug has doubled to almost 7 million worldwide, the company said. Net income rose 19 percent to $1.15 billion, or 96 cents a share, beating the average estimate of 95 cents a share from a survey of 30 analysts.
BUSINESS
November 5, 2004 | By Linda Loyd INQUIRER STAFF WRITER
Swiss researchers are reporting today in an international medical journal that evidence was clear and overwhelming in 2000 that Vioxx doubled the rate of heart attacks and that Merck & Co. Inc. should have withdrawn the drug four years ago. The analysis, by Peter Juni and colleagues at the University of Berne, looked at results from 18 Vioxx studies, all sponsored by Merck, which showed that 41 patients out of about 11,000 Vioxx users had suffered...
NEWS
November 11, 1990 | By Laurie Halse Anderson, Special to The Inquirer
The nine new buildings that Merck & Co. plan to construct in Upper Gwynedd by the year 2000 would mean many more cars coming into town. The company's plans include 3,000 parking spaces to accommodate those cars. Representatives of the pharmaceutical firm made the disclosure Thursday to the Township Board of Commissioners. The meeting, attended by about 20 residents, was an informational presentation that the board requested after residents raised concerns about the scope of the expansion and the impact it would have on the surrounding community.
NEWS
April 27, 2011 | ASSOCIATED PRESS
WASHINGTON - Federal health experts are recommending approval for a highly anticipated drug from Merck to treat hepatitis C, based on studies showing that it cures patients at a higher rate than drugs used for over 20 years. A Food and Drug Administration panel of experts voted unanimously, 18-0, in favor of Merck's boceprevir tablet as an effective treatment for hepatitis C, which affects an estimated 3.2 million Americans. The agency is not required to follow the group's recommendation, though it usually does.
BUSINESS
April 28, 2012 | By David Sell, INQUIRER STAFF WRITER
Merck & Co. Inc. reported a 67 percent profit increase Friday for the first quarter of this year compared with the same period in 2011, but the number was helped by cost-cutting and absence of a big charge from a year ago. The global drugmaker, which is based in Whitehouse Station, N.J., and has big operations in the Philadelphia suburbs, got the profit increase in part by spending less. "We're trying to manage our cost structure going forward," Merck chief executive officer Ken Frazier said in a conference call with Wall Street analysts.
BUSINESS
November 4, 2012 | By David Sell, Inquirer Staff Writer
Merck & Co. Inc., which made the controversial arthritis painkiller Vioxx, just settled an unusual class-action lawsuit involving Missouri residents who sued on consumer-fraud grounds without having shown that they incurred physical harm. The economic argument was that Vioxx did not provide what Merck claimed it would. Vioxx was on the market from 1999 until it was withdrawn in 2004 because previously hidden clinical trials showed that it caused increased risk of heart attacks. Merck has large operations in the Philadelphia region.
BUSINESS
January 3, 2008 | By Karl Stark INQUIRER STAFF WRITER
Top executives of PRWT Services Inc. were on hand at a Merck & Co. Inc. manufacturing plant in central Pennsylvania on New Year's Eve, shaking hands and greeting workers. The Philadelphia firm, which handles customer service for the Philadelphia Parking Authority and two others nationwide, had just branched out and taken over a giant pharmaceutical plant. The move, set to be celebrated by a ribbon-cutting ceremony tomorrow, created what its leaders called the nation's first minority-owned drug manufacturer.
NEWS
October 31, 1996 | By Douglas Belkin, INQUIRER CORRESPONDENT
Merck & Co., the chemical giant that employs about 5,800 people here, will be adding one more worker amenity to its array of volleyball courts, softball fields and jogging trails: day care. The township Board of Commissioners unanimously approved a 20,000-square-foot day-care center Monday night. The one-story facility will be built at the company's South Street and Sumneytown Pike property. Groundbreaking is scheduled for next month, and the facility may be open by late 1997, said Merck spokeswoman Tracy Patane.
NEWS
August 27, 2003 | By Kristin E. Holmes INQUIRER STAFF WRITER
John E. Baer, 86, of Lansdale, a pharmacologist and retired executive with what is now Merck & Co. Inc. who helped develop a groundbreaking series of drugs in the treatment of hypertension, died of respiratory failure Aug. 17 at Brittany Pointe Estates. Mr. Baer and three colleagues at what was then the Merck, Sharp & Dohme pharmaceutical company worked together in the early 1970s to develop thiazide diuretics. The medications control high blood pressure and prevent the accumulation of body fluid, often associated with heart disease.
NEWS
March 25, 1993 | by Jim Nicholson, Daily News Staff Writer
Emery "Simmie" Simms, a retired employee of the Merck Co., died Saturday. He was 85 and lived in West Philadelphia. Simms worked for Merck Co., formerly Merck, Sharpe & Dohme, for more than 30 years, primarily as a truck driver. He retired 23 years ago from the firm's facility in West Point, Montgomery County. "He was a very caring and generous man who loved his family and took care of everybody," said Sylvia Knight, a granddaughter. She said that if the weather was bad, her grandfather would telephone her to be sure she got home from work all right.
« Prev | 1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|